MedPath

Metoclopramide Use in Very Low Birth Weight Newborns

Phase 4
Completed
Conditions
Infant, Premature
Registration Number
NCT00242450
Lead Sponsor
Lawson Health Research Institute
Brief Summary

During the first 7 days of life very small babies will receive the drug metoclopramide or a salt solution through an intravenous line. They will also begin to receive a very small amount of breast milk or formula within the first 72 hours of life, in addition toother nourishment that is provided by an intravenous line, according to standard hospital procedure. We think that the babies who receive the medication may reach full oral feeds than babies who receive the salt solution.

Detailed Description

Clinically stable, premature babies (birth weight between 500 and 1,250g) will be randomized to receive metoclopramide (0.1 mg/kg IV q8h)or an equal volume of placebo for 7 days.A transition feeding schedule will begin within the first 72 hours of life. The time to full feeds for the 2 groups will be analyzed.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • birth weight 500 to 1,250g
  • clinically stable
  • no contraindications to initiating minimal enteral feeding
Exclusion Criteria
  • birth weight > 1,250g
  • clinically unstable
  • any major congenital anomaly
  • significant GI pathology
  • severe IUGR
  • cholestasis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Days required to attainment of full feeds.
Secondary Outcome Measures
NameTimeMethod
Weight at full enteral feeds (g).
Duration of TPN (days).
Weight at discharge (g).
Length of stay(days).

Trial Locations

Locations (1)

St Joseph's Hospital

🇨🇦

London, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath